Moderna (NASDAQ:MRNA - Get Free Report) had its price target cut by analysts at JPMorgan Chase & Co. from $33.00 to $26.00 in a report released on Thursday,Benzinga reports. The brokerage currently has an "underweight" rating on the stock. JPMorgan Chase & Co.'s price objective would indicate a potential upside of 1.42% from the company's current price.
A number of other brokerages also recently issued reports on MRNA. UBS Group cut their price objective on Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Citigroup began coverage on shares of Moderna in a report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price objective on the stock. Barclays lowered their price objective on Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research report on Friday, May 2nd. Bank of America dropped their price target on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday, February 11th. Finally, Royal Bank of Canada cut their price target on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Moderna has a consensus rating of "Hold" and an average target price of $53.58.
Check Out Our Latest Stock Report on Moderna
Moderna Price Performance
Shares of NASDAQ:MRNA traded down $0.16 during trading on Thursday, reaching $25.64. 1,277,719 shares of the company were exchanged, compared to its average volume of 7,976,576. The business's fifty day simple moving average is $27.39 and its 200-day simple moving average is $34.99. Moderna has a 12-month low of $23.15 and a 12-month high of $170.47. The firm has a market capitalization of $9.91 billion, a PE ratio of -2.77 and a beta of 1.99.
Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping the consensus estimate of ($2.92) by $0.40. The company had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. Moderna's revenue was down 35.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($3.07) EPS. On average, sell-side analysts anticipate that Moderna will post -9.61 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of MRNA. Norges Bank bought a new stake in Moderna in the fourth quarter valued at approximately $163,833,000. Voloridge Investment Management LLC boosted its holdings in shares of Moderna by 335.6% during the 4th quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company's stock worth $107,727,000 after buying an additional 1,996,003 shares during the period. FMR LLC grew its stake in Moderna by 7.4% in the 4th quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after buying an additional 1,282,469 shares during the last quarter. Pictet Asset Management Holding SA lifted its position in Moderna by 170.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock worth $73,447,000 after acquiring an additional 1,113,455 shares during the last quarter. Finally, SHANDA ASSET MANAGEMENT HOLDINGS Ltd bought a new stake in shares of Moderna during the first quarter worth approximately $28,350,000. Institutional investors own 75.33% of the company's stock.
Moderna Company Profile
(
Get Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
